Systemic inflammation and lung function in young adults

Robert J Hancox, Richie Poulton, Justina M Greene, Susan Filsell, Christene R Mclachlan, Finn Rasmussen, D Robin Taylor, Michael J A Williams, Avis Williamson, Malcolm R Sears

Background: Impaired lung function is associated with systemic inflammation and is a risk factor for cardiovascular disease in older adults. It is unknown when these associations emerge and to what extent they are mediated by smoking, chronic airways disease, and/or established atherosclerosis. We explored the association between the forced expiratory volume in one second (FEV₁) and the systemic inflammatory marker C-reactive protein (CRP) in young adults.

Methods: Associations between spirometric lung function and blood CRP were assessed in a population based birth cohort of approximately 1000 New Zealanders at ages 26 and 32 years. Analyses adjusted for height and sex to account for differences in predicted lung function and excluded pregnant women.

Results: There were significant inverse associations between FEV₁ and CRP at both ages. Similar results were found for the forced vital capacity. These associations were similar in men and women and were independent of smoking, asthma, and body mass index.

Conclusions: Reduced lung function is associated with systemic inflammation in young adults. This association is not related to smoking, asthma, or obesity. The reasons for the association are unexplained, but these findings indicate that the association between lower lung function and increased inflammation predates the development of either chronic lung disease or clinically significant atherosclerosis. The association between poor lung function and cardiovascular disease may be mediated by an inflammatory mechanism.

METHODS

Study members were born in Dunedin between April 1972 and March 1973. Assessments have been conducted throughout childhood and into adulthood. This analysis assesses the association between CRP and FEV₁ collected when the study members were aged 26 and 32 years. At each age 96% of living study members were assessed (980/1018 at age 26 and 972/1015 at age 32 years), although not all consented to both blood and lung function tests. The study members are mostly of New Zealand/European ethnicity with 7.5% identifying as Maori. Few study members identified with other ethnicities. The Otago ethics committee approved the study. Written informed consent was obtained at each assessment.

Methods

Study members were born in Dunedin between April 1972 and March 1973. Assessments have been conducted throughout childhood and into adulthood. This analysis assesses the association between CRP and FEV₁ collected when the study members were aged 26 and 32 years. At each age 96% of living study members were assessed (980/1018 at age 26 and 972/1015 at age 32 years), although not all consented to both blood and lung function tests. The study members are mostly of New Zealand/European ethnicity with 7.5% identifying as Maori. Few study members identified with other ethnicities. The Otago ethics committee approved the study. Written informed consent was obtained at each assessment.

Information obtained about respiratory health throughout the life course was updated at ages 26 and 32 years. Self-administered and interviewer administered questionnaires included selected questions from the American Thoracic Society and the European Community Respiratory Health Survey questionnaires. Current asthma is defined as self reported asthma with symptoms in the previous year. Current smoking was defined as smoking daily for at least one month during the past year. Cumulative smoking was calculated as the number of pack years (20 cigarettes per day for 1 year = 1 pack year). At both ages 26 and 32 years, participants were asked if they currently had any kind of cancer, arthritis, heart problems, had ever been told that they had diabetes or high blood sugar (excluding gestational), or had had either a kidney or bladder infection or a surgical operation requiring a general anaesthetic in the past 12 months. Study members reporting any of these problems were regarded as having a recent or current health problem. At both ages, Study members were also asked if they had smoked cannabis in the previous year.

Abbreviations: BMI, body mass index; CRP, C-reactive protein; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; IQR, interquartile range.
At both assessments height and weight in light clothing without shoes were measured. Spirometry was performed using SensorMedics body plethysmograph (Yorba Linda, CA, USA) according to American Thoracic Society standards before and after 200 μg salbutamol via a large volume spacer. Study members were seated in the plethysmograph and wore nose pegs. At least three acceptable manoeuvres were obtained with the best FEV₁ and forced vital capacity (FVC) from any of the acceptable tests reported and used for calculation of FEV₁/FVC. A portable spirometer (Spiropro, Sensormedics, Yorba Linda CA, USA) was used to test study members (n = 27) who refused to sit in the plethysmograph or were unable to attend the research unit. Participants were asked to avoid using any of their inhalers on the day of the test. Tests were reviewed by a senior technician to ensure only acceptable and reproducible results were entered for analysis. Equipment was calibrated daily and weekly quality control measures were obtained to ensure accuracy and precision of equipment.

At both ages blood samples were obtained approximately 4 hours after lunch. The following assays were performed using a Hitachi 917 analyser: at age 26 years serum CRP by immunoturbidimetric assay (coefficient of variation 5.6–12.9%, Boehringer Mannheim, Germany); at age 32 years, CRP was measured using a high sensitivity particle enhanced immunoturbidimetric assay (coefficient of variation 5.6–2.8%, Roche Diagnostics, Germany).

Analyses
Mean values of percentage predicted FEV₁ were compared across groups with low, medium, and high CRP values at each age. Cross sectional associations between CRP and FEV₁ were further analysed by multiple linear regression using absolute values of FEV₁ (in ml) as the dependent variable and CRP as the main predictor with adjustment for height and sex. CRP values were transformed using natural logarithms to approximate normal distributions (a value of 1 was added to all age 26 CRP values to allow log transformation of zero values). All analyses adjusted for sex. Plots of residual versus fitted values were visually inspected to ensure an approximately random distribution of residuals around the fitted values. The linearity assumptions of the models were checked by fitting quadratic and cubic terms for log-CRP. Neither was significant at either age. Supplementary analyses tested for interactions between sex and FEV₁, analysed sexes separately, and were restricted to those who had never smoked and had never had asthma and reported no recent other health problems. Analyses were repeated including terms for body mass index, current smoking, and current asthma in the model. Analyses were repeated using the FVC, the FEV₁/FVC ratio, and the post-bronchodilator FEV₁ as dependent variables.

To test the hypothesis that systemic inflammation leads to an accelerated decline in lung function, we used linear regression to test if log-CRP at age 26 predicted the change in FEV₁ (ml) from age 26 to age 32 years, adjusting for sex, smoking between age 26 and 32, and asthma at either age. To test the alternative hypothesis that a decline in FEV₁ leads to an increase in inflammation, we used linear regression to test whether the change in FEV₁ between ages 26 and 32 years predicted log-CRP at age 32, adjusting for sex, smoking between age 26 and 32 years, and asthma at either age.

### Table 1 Study member characteristics at age 26 and 32 years

<table>
<thead>
<tr>
<th>Age</th>
<th>Women</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CRP category</td>
<td>No (% FEV₁)</td>
</tr>
<tr>
<td>26</td>
<td>Low (&lt;1 mg/l)</td>
<td>104 (107.3)</td>
</tr>
<tr>
<td></td>
<td>Medium (1–3 mg/l)</td>
<td>108 (102.8)</td>
</tr>
<tr>
<td></td>
<td>High (≥3 mg/l)</td>
<td>167 (100.0)</td>
</tr>
<tr>
<td>32</td>
<td>Low (&lt;1 mg/l)</td>
<td>166 (106.6)</td>
</tr>
<tr>
<td></td>
<td>Medium (1–3 mg/l)</td>
<td>126 (105.7)</td>
</tr>
<tr>
<td></td>
<td>High (≥3 mg/l)</td>
<td>110 (101.7)</td>
</tr>
</tbody>
</table>

Pregnant women are excluded. CRP, C-reactive protein; FEV₁, forced expiratory volume in one second; 95% CI = 95% confidence intervals for mean. p values for trend across CRP categories.
Pregnant women (n = 33 at age 26, n = 31 at 32) were excluded from all analyses, which were performed using Stata 9.1 (StataCorp, College Station, TX, USA).

RESULTS
Cross sectional associations
The characteristics of the study population at ages 26 and 32 are shown in table 1. CRP levels at both ages were significantly higher in women than men (p < 0.001). The mean FEV₁ was lower at age 32 than age 26 (p = 0.0003) and the fall in FEV₁ between age 26 and 32 was greater in men (0.22 litres) than women (0.05 litres) (p < 0.0001). Based on local reference equations, the mean (SD) FEV₁ values were 102.4% (12.8) and 78.8% (11.7) at age 26 and 32 years in regression analyses adjusting for sex and height, respectively. The sex adjusted partial correlation coefficients between measurements at age 26 and age 32 years were r = 0.88 (p < 0.001) for FEV₁, and r = 0.37 (p < 0.001) for log-CRP. Analyses of categorised low, medium, high CRP values (as defined by the American Heart Association/Centers for Disease Control) demonstrated decreasing percentage predicted FEV₁ with increasing CRP in women at both ages (p < 0.01) and in men at age 32 (p < 0.01) but this was not significant in 26-year-old men (p = 0.09) (table 2).

FEV₁ values were inversely associated with log-CRP at both age 26 and age 32 years in regression analyses adjusting for sex and height (table 3). Associations between lung function and CRP were not significantly different between women and men (p value for interaction = 0.29 at age 26, p = 0.83 at age 32) or between Maori and non-Maori (p value for interaction = 0.61 at age 26, p = 0.51 at age 32). The findings were similar when the analysis was restricted to study members who had never had asthma and had never smoked (table 3). The associations between FEV₁ and log-CRP remained significant after including terms in the regression model to adjust for body mass index, current asthma, and current smoking (table 3). Analyses excluding all those reporting other health problems, past year cannabis smoking, current smoking or current asthma also provided similar findings (age 26; n = 205, coefficient = −96, p = 0.016: age 32; n = 285, coefficient = −70, p = 0.006).

Similar associations between lung function and log-CRP were found for the post-bronchodilator FEV₁ (data not shown). For the FVC there was a significant sex × log-CRP interaction at age 32 (p = 0.03) and although both sexes showed significant inverse associations between log-CRP and FVC at both ages, these tended to be greater in men (see Thorax website, http://thorax.bmj.com supplemental, table 1). There were also significant interactions between sex and log-CRP for the FEV₁/FVC ratio at both ages. The FEV₁/FVC ratio was inversely associated with CRP only in women. At age 32 this association was no longer significant after adjusting for smoking status (see Thorax website, http://thorax.bmj.com supplemental, table 2).

Longitudinal associations between age 26 and 32
Log-CRP at age 26 was not a significant predictor of the change in FEV₁ between ages 26 and 32 adjusting for sex and height (table 4). By contrast, the decrease in FEV₁ between age 26 and 32 years was a significant predictor of log-CRP at age 32 years. The sex × change in FEV₁ interaction term was not significant (p = 0.72) indicating that this longitudinal association was of similar magnitude in men and women. This association remained significant after adjusting for log-CRP at age 26, history of smoking between age 26 and 32, and asthma diagnosis at either age (table 4).

DISCUSSION
We have identified an association between spirometric lung volumes, and systemic inflammation, measured by serum C-reactive protein, in young adults aged 26 and 32 years. This

---

**Table 3** Regression of FEV₁ on log-CRP

<table>
<thead>
<tr>
<th>Age</th>
<th>Adjustments and model restrictions</th>
<th>No</th>
<th>Coefficient (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>Sex, height</td>
<td>816</td>
<td>−86 (−125 to −48)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Height</td>
<td>379</td>
<td>−89 (−130 to −49)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Height (men only)</td>
<td>437</td>
<td>−78 (−145 to −10)</td>
<td>0.024</td>
</tr>
<tr>
<td></td>
<td>Sex, height (never asthma, never smokers)</td>
<td>315</td>
<td>−85 (−147 to 24)</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td>Sex, height, BMI, smoking*, asthma*</td>
<td>811</td>
<td>−75 (−115 to −35)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>32</td>
<td>Sex, height</td>
<td>850</td>
<td>−82 (−116, −49)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Height (men only)</td>
<td>402</td>
<td>−72 (−108 to −35)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Height (men only)</td>
<td>448</td>
<td>−74 (−151 to −38)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>Sex, height (never asthma, never smokers)</td>
<td>309</td>
<td>−58 (−109 to −7)</td>
<td>0.027</td>
</tr>
<tr>
<td></td>
<td>Sex, height, BMI, smoking*, asthma*</td>
<td>850</td>
<td>−73 (−108 to −38)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

CRP, C-reactive protein; FEV₁, forced expiratory volume in one second; BMI, body mass index.

Coefficients refer to the change in FEV₁ in ml for each standard deviation increase in log-CRP. Analyses exclude pregnant women. * Adjustment for current (past year) smoking and asthma. BMI, body mass index (kg/m²).

---

**Table 4** Longitudinal analyses of the association between decline in FEV₁ from age 26 to 32 and CRP at age 26 and 32

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Predictor</th>
<th>Covariates</th>
<th>n</th>
<th>Coefficient (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fall in FEV₁ (ml)</td>
<td>Age 26 age 32</td>
<td>Sex, height</td>
<td>766</td>
<td>−3.30 (−25.1 to 18.5)</td>
<td>0.77</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex, height, smoking*, asthma*</td>
<td>765</td>
<td>−2.55 (−24.4 to 19.3)</td>
<td>0.82</td>
</tr>
<tr>
<td>Age 32 log-CRP</td>
<td>Fall in FEV₁ (litres)</td>
<td>Sex, height</td>
<td>788</td>
<td>0.48 (0.25 to 0.71)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex, height, smoking*, asthma*, age 26 CRP</td>
<td>739</td>
<td>0.49 (0.26 to 0.71)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

CRP, C-reactive protein; FEV₁, forced expiratory volume in one second.

CRP values were log transformed for analysis and are expressed as standard deviation scores. Analyses exclude women who were pregnant at either age. * Analyses adjusted for history of smoking between age 26 and 32 years and current asthma diagnosis at either age.
association was of similar magnitude in women and men and was independent of smoking, asthma and body mass index.

To our knowledge, this is the first report of an inverse association between lung function and CRP in young adults. There are numerous reports of increased markers of systemic inflammation in older adults with stable chronic obstructive pulmonary disease.20–31 These markers appear to reflect disease severity and functional status.10–12 This has usually been interpreted as being the result of the inflammatory nature of the airway disease.22–23 Since systemic inflammation is a risk factor for atherosclerosis, it has been suggested that this is one reason why patients with chronic obstructive pulmonary disease have an increased risk of cardiovascular disease.6–23 However, we have found that the association of a higher serum CRP with lower lung function is present as early as age 26 years. By this age it is very unlikely that members of this cohort will have developed either clinically significant atherosclerosis or chronic obstructive pulmonary disease. A recent report identified an inverse association between plasma fibrinogen and lung function in apparently healthy young American adults (average age 30).24 Taken together, these findings indicate that there is an association between lung function and systemic inflammation, which predates the clinical development of either disease. Moreover, the associations are equally strong in those who have never smoked and do not have asthma. Although these are prominent risk factors for the development of chronic lung disease it is clear that they do not explain the association between lung function and systemic inflammation in these young adults. The finding that association between lower lung function and CRP was independent of body mass index is important because obesity is an established risk factor for systemic inflammation in young people, a finding that has been confirmed in an earlier report from this cohort,25 and body size measurements may also influence lung function.26

These findings may help to explain epidemiological observations that have been made in older populations and are consistent with the hypothesis that systemic inflammation mediates the association between reduced lung function and cardiovascular disease. Firstly, the association between FEV1 and systemic inflammation was present in those who had never smoked and did not have asthma or other health problems. This is consistent with several observations that reduced lung function predicts cardiovascular mortality independently of smoking and is also consistent with the inverse association between CRP and lung function recently reported among apparently healthy older adults (mean age 50) attending for health screening26 and in general population surveys (mean ages 37 and 44).27–28 Secondly, the fall in FEV1 between age 26 and 32 was a significant predictor of blood CRP at age 32 years. This may help to explain the association between rapid FEV1 decline and cardiovascular mortality.29

Establishing whether systemic inflammation leads to reduced lung function or whether lower lung function leads to inflammation is difficult. In the longitudinal analyses CRP at age 26 did not predict the decline in FEV1 over the following six years. By contrast, the decline in FEV1 between ages 26 and 32 was a strong and significant predictor of CRP at age 32. Two other longitudinal studies in older adults also found that baseline CRP levels did not predict changes in lung function over the following 8–9 years but both found associations between decline in FEV1 and rising CRP levels.27–28 This suggests that systemic inflammation may be a consequence of a decline in lung function rather than the cause of the decline. However, CRP is an acute phase protein with a short half-life and a much less stable measure than FEV1. Moreover, the CRP measurements at age 26 used a low sensitivity assay. Therefore the measurement taken at age 26 may not accurately reflect the level of inflammation over the following six years. In the CARDIA study, plasma fibrinogen measured at mean age 30 appeared to predict the decline in spirometric lung volumes over the subsequent five years.27 This study did not have repeat measurements of fibrinogen after five years in order to test whether decline in lung function predicted systemic inflammation.

The association of lower spirometric lung volumes and systemic inflammation could have several explanations. It is possible that systemic inflammation damages pulmonary tissue and hence leads to deteriorating lung function. However, we found that the association was equally strong in apparently healthy study members (excluding ever smokers and those with asthma, arthritis, heart disease, cancer, diabetes, and recent major surgery or urinary tract infections). Although we will have missed some undiagnosed problems and conditions affecting other systems, this suggests that the association is unlikely to be mediated by a systemic inflammatory response to another disease process. An alternative explanation is that inflammation within the lungs may be the cause of the systemic inflammatory response, although it is clear from our findings that this inflammation is not caused by either asthma or smoking. The lungs may also have an anti-inflammatory role, particularly as a primary defence organ against environmental toxins and it is possible that this is why people with lower lung function have increased systemic inflammation. Finally, it is possible that other factors cause both a reduction in lung function and systemic inflammation. For example, a reduced dietary intake of anti-oxidants and vitamins has been linked to both lower lung function33–35 and higher levels of CRP.34–36 Alternatively CRP levels and lung function are likely to be influenced by genes and it is possible that these genetic influences overlap.

We analysed the data using the absolute value of FEV1 adjusting for height in the analyses rather than use FEV1 as a percentage of predicted. This is in accordance with the recommendations of Vollmer et al.37 Repeat analyses using the FEV1 as percentage predicted produced the same pattern of results as did analyses using FVC and the post-bronchodilator FEV1. The association between the FEV1/FVC ratio and CRP was weaker and only significant in women (see Thorax website, http://thorax.bmj.com/supplemental, table 2). Similarly, plasma fibrinogen has been found to be associated with lower FEV1 and FVC measurements but not with reduced FEV1/FVC ratios.24 This suggests that the association between lung function and systemic inflammation is more closely related to spirometric lung volumes rather than airflow obstruction.

A limitation of this study is that the measurement of CRP at age 26 years used a low sensitivity assay. It is now believed that low grade inflammation, which may impact on cardiovascular risk, may be associated with CRP levels that are not accurately detected by standard CRP assays.3 The low sensitivity assay at age 26 may have reduced our chance of detecting a prospective association between the initial CRP value and the subsequent decline in FEV1. The differences in the assay methods may also explain the apparent fall in mean CRP levels between age 26 and 32 years. Nevertheless, CRP measurements taken at age 32 years using a high sensitivity assay provided similar cross sectional associations between CRP and FEV1 to those found at age 26 using a low sensitivity assay.

This investigation has a number of strengths. We have found similar results at two ages in a general population based cohort with a high rate of participation. The cohort members have similar health status to nationally representative samples of young adult New Zealanders29 and the distribution of CRP values is similar to that described for similar age participants in
other studies. We have prospectively collected information on smoking and asthma and have directly measured height and weight. Lung function was measured using the same equipment for all study members and the blood samples were assayed in the same laboratory at each age.

In summary, there is a significant inverse relation between spirometric lung volumes and systemic inflammation in young adults. This association is independent of smoking and asthma history and is also independent of body mass index. While the underlying reason for this association is uncertain, the findings suggest a plausible mechanism by which a reduced FEV₁ is associated with an increased risk of cardiovascular disease in a manner that is independent of smoking and known respiratory disease.

Acknowledgements

We are grateful to the study members and families of the Dunedin study for their continued support. We also thank Dr Phil A Silva, the study founder. Professor Avshalom Caspi provided access to data and helpful comments on the findings. The Dunedin Multidisciplinary Health and Development Research Unit is funded by the Health Research Council of New Zealand. Dr Sears holds the AstraZeneca Chair in Respiratory Epidemiology at McMaster University.

Further tables can be found on Thorax website, http://thorax.bmj.com/supplemental

Authors’ affiliations

Robert J Hancox, Richie Poulton, Susan Filsell, Christene R McLachlan, Avis Williamson, Dunedin Multidisciplinary Health and Development Research Unit, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

Justina M Greene, Malcolm R Sears, Firestone Institute for Respiratory Health, St. Joseph’s Healthcare and Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Finn Rasmussen, Department of Respiratory Diseases, Aarhus Community Hospital, Aarhus University, Denmark

D Robin Taylor, Michael J A Williams, Department of Medical and Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

References


Downloaded from http://thorax.bmj.com/ on April 1, 2017 - Published by group.bmj.com
Systemic inflammation and lung function in young adults.

Online supplement
<table>
<thead>
<tr>
<th>Age</th>
<th>Adjustments and model restrictions</th>
<th>n</th>
<th>Coefficient (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>sex, height</td>
<td>816</td>
<td>-0.7 (-1.2, -0.2)</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td>women only</td>
<td>379</td>
<td>-1.2 (-1.8, -0.6)</td>
<td>0.012</td>
</tr>
<tr>
<td></td>
<td>men only</td>
<td>438</td>
<td>-0.1 (-0.9, 0.7)</td>
<td>0.86</td>
</tr>
<tr>
<td></td>
<td>sex (never asthma, never-smokers)</td>
<td>316</td>
<td>-0.2 (-0.9, 0.5)</td>
<td>0.62</td>
</tr>
<tr>
<td></td>
<td>sex, BMI, smoking*, asthma*</td>
<td>811</td>
<td>-0.4 (-0.9, 0.1)</td>
<td>0.13</td>
</tr>
<tr>
<td>32</td>
<td>sex, height</td>
<td>850</td>
<td>-0.3 (-0.8, 0.1)</td>
<td>0.14</td>
</tr>
<tr>
<td></td>
<td>women only</td>
<td>403</td>
<td>-0.8 (-1.3, -0.2)</td>
<td>0.010</td>
</tr>
<tr>
<td></td>
<td>men only</td>
<td>449</td>
<td>0.2 (-0.5, 0.8)</td>
<td>0.63</td>
</tr>
<tr>
<td></td>
<td>sex (never asthma, never-smokers)</td>
<td>310</td>
<td>0.1 (-0.5, 0.6)</td>
<td>0.84</td>
</tr>
<tr>
<td></td>
<td>sex, BMI, smoking*, asthma*</td>
<td>850</td>
<td>-0.3 (-0.8, 0.1)</td>
<td>0.15</td>
</tr>
</tbody>
</table>

Table 1. Regression of FVC on log-CRP.
Coefficients refer to the change in FVC in mL for each standard deviation increase in log-CRP. Analyses exclude pregnant women. *Adjustment for current (past year) smoking and asthma. BMI = body mass index (kg/m²).

<table>
<thead>
<tr>
<th>Age</th>
<th>Adjustments and model restrictions</th>
<th>n</th>
<th>Coefficient (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>sex, height</td>
<td>816</td>
<td>-77 (-120, -35)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>height (women only)</td>
<td>379</td>
<td>-56 (-101, -12)</td>
<td>0.014</td>
</tr>
<tr>
<td></td>
<td>height (men only)</td>
<td>437</td>
<td>-96 (-169, -22)</td>
<td>0.011</td>
</tr>
<tr>
<td></td>
<td>sex, height (never asthma, never-smokers)</td>
<td>315</td>
<td>-99 (-172, -26)</td>
<td>0.008</td>
</tr>
<tr>
<td></td>
<td>sex, height, BMI, smoking*, asthma*</td>
<td>811</td>
<td>-76 (-120, -31)</td>
<td>0.001</td>
</tr>
<tr>
<td>32</td>
<td>sex, height</td>
<td>850</td>
<td>-90 (-129, -51)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>height (women only)</td>
<td>402</td>
<td>-52 (-95, -8)</td>
<td>0.020</td>
</tr>
<tr>
<td></td>
<td>height (men only)</td>
<td>448</td>
<td>-134 (-199, -71)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>sex, height (never asthma, never-smokers)</td>
<td>309</td>
<td>-78 (-140, -16)</td>
<td>0.014</td>
</tr>
<tr>
<td></td>
<td>sex, height, BMI, smoking*, asthma*</td>
<td>850</td>
<td>-77 (-119, -35)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Table 2. Regression of FEV₁/FVC ratio on log-CRP.
Coefficients refer to the change in FEV₁/FVC percent for each standard deviation increase in log-CRP. Analyses exclude pregnant women. *Adjustment for current (past year) smoking and asthma. BMI = body mass index (kg/m²).
Systemic inflammation and lung function in young adults.

Robert J Hancox, Richie Poulton, Justina M Greene, Susan Filsell, Christene R McLachlan, Finn Rasmussen, D Robin Taylor, Michael J A Williams, Avis Williamson and Malcolm Sears

Thorax published online June 29, 2007

Updated information and services can be found at:
http://thorax.bmj.com/content/early/2007/06/29/thx.2006.076877

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2007/11/22/thx.2006.076877.DC1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Inflammation (1020)
- Health education (1223)
- Smoking (1037)
- Tobacco use (1039)
- Child health (843)
- Tobacco use (youth) (191)
- Airway biology (1100)
- Lung function (773)
- Asthma (1782)
- Obesity (public health) (197)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/